YBCSG 2025 Mid-Year Meeting | Prof. Hengyu Li: Advancing Liver Metastasis Management and Multidisciplinary Collaboration to Bring Hope to Breast Cancer Patients

YBCSG 2025 Mid-Year Meeting | Prof. Hengyu Li: Advancing Liver Metastasis Management and Multidisciplinary Collaboration to Bring Hope to Breast Cancer Patients

2025.08.04
The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation titled “Treatment Challenges of Breast Cancer Liver Metastases in 2025.” In an exclusive interview with Oncology Frontier, Prof. Li elaborated on YBCSG’s major achievements in the first half of 2025 and highlighted key challenges in managing liver metastases in breast cancer.
YBCSG 2025 Mid-Year Meeting | Prof. Leiping Wang: Latest Advances in HER2-Positive Breast Cancer at ASCO 2025 and Reflections on Clinical Practice

YBCSG 2025 Mid-Year Meeting | Prof. Leiping Wang: Latest Advances in HER2-Positive Breast Cancer at ASCO 2025 and Reflections on Clinical Practice

2025.08.04
At the recent "Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association," Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier invited Prof. Wang for an exclusive interview to share insights on the key findings presented at the ASCO 2025 conference in the field of HER2-positive breast cancer and their clinical implications, along with perspectives on future research directions.
Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

Breakthrough in Bladder Cancer Treatment! Lin Tianxin and Chen Xu’s Team at Sun Yat-sen University First to Demonstrate Safety and Preliminary Efficacy of Intravesical Disitamab Vedotin in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

2025.08.01
A research team led by Professor Lin Tianxin and Professor Chen Xu from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University has published clinical trial results in the prestigious journal MedComm, titled “Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose–Escalation Phase I Trial Study.” This marks the world’s first clinical study to evaluate the intravesical administration of the HER2-targeted antibody–drug conjugate (ADC) disitamab vedotin (RC48) in patients with HER2-positive high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The study offers a novel bladder-sparing strategy for patients who are unresponsive or intolerant to Bacillus Calmette-Guérin (BCG) therapy.
Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025

Exclusive Interview with EHA President | Professor Martin Dreyling: Unmissable Breakthroughs in Myeloma, Leukemia, and Lymphoma at EHA 2025

2025.07.31
The 2025 European Hematology Association (EHA) Annual Congress was successfully held from June 12 to 15 in Milan, Italy. Marking the 30th anniversary of the EHA, this year’s congress stood out as a major milestone, drawing over 15,000 experts and scholars from around the world with its global impact and groundbreaking research highlights. During the event, Oncology Frontier – Hematology Frontier had the privilege of speaking with Professor Martin Dreyling, Chair of the EHA 2025 Scientific Program Committee (SPC) and a professor at LMU Munich, to explore the most transformative scientific advances presented at the meeting.
EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?

EHA Highlight | Professor Evangelos Terpos: A Comprehensive Upgrade in MM Management—What’s New in the 2025 EHA-EMN Clinical Guidelines?

2025.07.31
At the 2025 Annual Congress of the European Hematology Association (EHA), the much-anticipated updated EHA-EMN clinical practice guidelines for multiple myeloma (MM) were officially released. Covering key areas such as diagnostic assessment, risk stratification, treatment pathways, and follow-up management, the new guidelines provide more forward-thinking and practical guidance for clinical implementation.
Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres

2025.07.30
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress hosted by the Chinese Society of Clinical Oncology (CSCO) took place in Harbin. The conference brought together leading experts from China and abroad to discuss key topics in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics ranged from basic research and innovative drug development to precision medicine strategies and clinical translation. At the conference, Professor Yu Zhang from Southern Hospital of Southern Medical University delivered a compelling presentation titled “Optimizing the Diagnostic and Treatment Pathway for AML at Southern Hospital.” In an exclusive interview with Oncology Frontier – Hematology Frontier, Professor Zhang shared further insights into the hospital’s innovative approaches and practical experiences in managing acute myeloid leukemia (AML).